168 results
424B5
TPST
Tempest Therapeutics Inc
20 Jun 24
Prospectus supplement for primary offering
8:32am
, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our
directors then in office … had no reasonable cause to believe his or her conduct was unlawful.
Super Majority Voting
The DGCL provides generally that the affirmative vote
8-K
EX-4.1
TPST
Tempest Therapeutics Inc
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
of which a (i) a majority of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by such Person or (ii … ) an amount of securities or other ownership interests having ordinary voting power sufficient to elect at least a majority of the directors or other
8-K
EX-3.1
8skbatd6pf
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
8-K
EX-10.2
as7aigj
21 Jun 22
Departure of Directors or Certain Officers
7:31am
8-K
EX-10.1
qtfse2c1c
21 Jun 22
Departure of Directors or Certain Officers
7:31am
8-K
EX-99.1
ef9b3dnhlfh xm1cg6gn
9 Jun 22
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
8:08am
424B3
0aowlsfkuifr15
27 May 22
Prospectus supplement
9:01am
8-K
EX-99.1
fftnvqc1 8xjrzab6
26 May 22
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting
5:06pm
DEFA14A
beibn
9 May 22
Additional proxy soliciting materials
8:01am